Financial results for the first half of 2011
Strong validation for Innate Pharma’s two most advanced programs Controlled burn rate and strong cash position Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate...
Financials and Corporate
Half-year report on Innate Pharma's liquidity contract with Natixis Securities
Under the liquidity contract entrusted by Innate Pharma to Natixis Securities, the following assets appeared on the liquidity account as at June 30, 2011: 121,882 shares of Innate Pharma, and 33,311...
Innate Pharma announces today the outcome of its Annual General Meeting which took place on June 29, 2011, in Marseilles, France
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its Annual General Meeting (“AGM”) which took place on June 29, 2011, in Marseilles, France. A number of 26,483,176...
Innate Pharma to hold its Annual General Meeting of Shareholders on June 29, 2011, in Marseilles, France
Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 29, 2011, at 9:30 am in its headquarters, 117 avenue de Luminy, F-13009...
Appointment of Catherine Moukheibir to the Executive board of Innate Pharma
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the reinforcement of its management with the appointment of Catherine Moukheibir to its Executive board, as Senior Advisor Finance.
Innate Pharma announces its turnover for the first quarter of 2011 and updates on its cash position
Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces a turnover of 1.0 million euros for the first quarter of 2011, compared with 0.1 million euros (105 thousand euros) for the...
Innate Pharma and Transgene Announce the Creation of Platine Pharma Services, a New Company Specialized in Immunomonitoring Services
• Created on the basis of an existing collaborative platform, Platine Pharma Services is owned equally by Innate Pharma and Transgene. • Platine’s ambition is to become a European leader in...
Innate Pharma announces the release of its Reference Document (in French)
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the French version of the 2010 Reference Document, including the Annual Financial Report, is available on its website (www.innate...
Innate Pharma updates on its next meetings with analysts and investors
Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that it will participate to the following analyst and investor conferences in the coming weeks: Benelux Midcap Event in...
Innate Pharma reports 2010 financial results and updates on its drug candidates
Strong balance sheet and controlled cash burn Two drug candidates in clinical trials, one of which licensed to Novo Nordisk A/S Six clinical trials in the US and Europe for IPH 21 program Innate...